Remission of In-Transit Melanoma following Combination BRAF and MEK Inhibition Therapy: A Case Report

S Caleb Freeman1, Edibaldo Silva2 and Christopher Huerter1

1Department of Dermatology, Creighton University School of Medicine, USA
2Department of Surgical Oncology, University of Nebraska Medical Center, USA

Introduction

Satellite and in-transit melanoma represent the metastasis of cutaneous melanoma along lymphatics between the primary lesion and the regional lymph nodes. In-transit melanoma often presents as a reoccurrence of previously resected melanoma, and as such is associated with a poorer prognosis than primary melanoma [1]. Response rate to therapy is often suboptimal, with 5-year survival rates of 24-54% at 5 years [2]. Treatment protocols for in-transit melanoma are less standardized than many other clinical scenarios, but possibilities for treatment include surgical removal, palliative radiotherapy, isolated limb perfusion, intra-lesional T-VEC injections, systemic targeted therapy and immunotherapy [3]. This case presents a successful selective approach for the management of refractory in-transit melanoma that included treatment with combination BRAF inhibitor dabrafenib and MEK inhibitor trametinib for a patient with stage IV melanoma.

Case Report

A 58-year-old white woman was referred for a 2.5-cm enlarging blackish brown patch on her left medial ankle that had recently begun bleeding. An excisional biopsy found malignant nodular melanoma with positive margins. She underwent wide re-excision and sentinel lymph node biopsy. Results showed residual malignant nodular melanoma with a Breslow depth of 1.1 mm, Clark’s level IV with negative margins. All 3 sentinel lymph nodes in the left groin were negative. She was followed clinically for 4 years, at which point she developed an extensive amount of new pigmented nodules scattered on her left lower extremity (Figure 1). Biopsies were taken of a left pretibial nodule as well as a left lower lateral pretibial nodule. Both were consistent with malignant melanoma in-transit metastases that tested positive for a BRAF V600E mutation. In the absence of systemic metastases by PET scan, initial treatment consisted of heated isolated limb infusion with the alkylating agent melphalan 7.5 mg per liter of volume, adjusted for patient’s ideal body weight. While the patient initially showed improvement, with a near complete resolution of her in-transit leg disease for a period of 6 months, she later developed a painful pre-tibial mass on the leg which was treated with palliative radiation therapy. Unfortunately, and as often seen following in-transit disease, the patient developed progressive soft tissue metastases outside the perfused extremity, with new lesions appearing in the right shoulder and occiput. Based on the cross-over sensitivity of BRAF positive disease to systemic immunotherapy, she was treated with 4 cycles of pembrolizumab administered at 2 mg/kg every 2 weeks. Evidence of progression on this regimen led to a switch over to BRAF-targeted therapy with dabrafenib and trametinib. Patient received 150 mg dabrafenib every 12 hours and 2 mg trametinib once daily. As often seen, she showed complete resolution of nearly all disease within 4 weeks. Four months after completing treatment the skin and subcutaneous tissue remained clear (Figure 2). Patient remains on combination therapy to date.

Discussion

Combined dabrafenib and trametinib therapy is a potential therapeutic option for the treatment of BRAF-positive in-transit melanoma metastases resistant to other therapies. This patient’s disease was refractory to multiple traditional treatment regimens for in-transit melanoma, including isolated limb infusion and immune checkpoint therapy.

Both dabrafenib and trametinib were originally approved as monotherapy for BRAF V600 mutation-positive metastatic melanoma. In a phase III trial, therapy with dabrafenib, a BRAF inhibitor, showed a 50% response rate and progression-free survival of 5.1 months [4].

Trametinib also targets the MAPK pathway by inhibiting MEK, a BRAF substrate. Median progression-free survival of trametinib in a phase III trial was 4.8 months with an overall survival of 81% [5]. However, a common mechanism of resistance to these treatments in monotherapy is the

*Corresponding author: S Caleb Freeman, Department of Dermatology, Creighton University School of Medicine, USA

Accepted: January 17, 2019

Published online: January 19, 2019

development of bypass pathways such as MAPK reactivation [6]. Previous studies showed that resistance to monotherapy with a BRAF inhibitor such as dabrafenib developed within 6 to 7 months of initiating therapy in 50% of patients [7].

Because dabrafenib and trametinib both target the same pathway but via different mechanisms, combination therapy is now the preferred option to limit the development of resistance and thus improve outcomes [8]. The phase III clinical trial COMBI-d compared therapy with both dabrafenib and trametinib to dabrafenib alone. Results showed a 25% reduction in the risk of progression or death [9]. A separate study showed that combined therapy inhibiting both BRAF and MEK showed an improved response when compared to monotherapy, with 70% of patients experiencing a complete or partial response within a year [10].

This patient presently remains on combination therapy with dabrafenib and trametinib. Currently no guidelines for cessation of treatment exist, and physicians must balance the potential hazard of discontinuing combination treatment with the immense financial burden this treatment method places on both the patient and health care system. Further research and analysis is needed to guide physicians in determining
a length of therapy for patients treated with combination therapy.

This case demonstrates the selective and orderly application of newly available but limited local and systemic options for the treatment of BRAF V600 mutation-positive in-transit melanoma. Because treatment for in-transit melanoma is less standardized than other variants of melanoma, and in view of its predilection for subsequent systemic failure, the choice of available options may differ from individual to individual. The goal should be the complete resolution of disease while keeping in mind that distant metastases may lurk in the background for which there are limited options at hand should they become evident on follow up. In addition, the complete resolution of this patient’s disease within 4 weeks reaffirms the efficacy of using combination therapy for in-transit melanoma with distant metastases.

References